Company intelligence / Profile preview

Starna

Suzhou, Jiangsu, China

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Starna Therapeutics is a biotechnology company specializing in the development of next-generation RNA therapeutics using its proprietary STAR (Selective Tissue-targeting RNA) platform. The company focuses on mRNA and circular RNA (circRNA) technologies, coupled with advanced lipid nanoparticle (LNP) delivery systems that enable extrahepatic targeting. Starna's pipeline includes programs for infectious diseases, oncology, and rare genetic disorders. By optimizing RNA stability and tissue specificity, the company aims to overcome current limitations in RNA drug delivery and expression.

Therapeutic areas: Infectious DiseasesRare DiseasesMetabolic DisordersOncology
Modalities: mRNA-based drugsRNA therapyLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on Starna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Starna.

Explore the full profile